Abstract 58P
Background
There is an increasing incidence of RC in the young. Clinicopathologic features are not clearly established especially in the local Filipino population. Moreover, treatment challenges occur in this population. This study aims to describe the clinicopathologic profile and outcomes in patients diagnosed with RC in the young at the Southern Philippines Medical Center, Adult Cancer Institute.
Methods
All RC patients were reviewed from January 2018 to December 2021. A total of 548 RC patients were reviewed retrospectively.
Results
A total of 99 patients were identified (18%) as RC in the young. Majority were males (68%) and have a family history of cancer (72%). Mean tumor distance was 4.82+6.0 cm from the anal verge. All patients had adenocarcinoma histology with 9% having mucinous component and 1% with signet ring features. For tumor differentiation, 56% had moderately and 23% had poorly differentiated tumors. Most patients were diagnosed with locally advanced disease (55% St IIIB, 12% St IIIC) and 24% with distant metastasis. Mean CEA levels were elevated (preoperative 59.44ng/ml and post-operative 49.42ng/ml). Among non-metastatic disease, most stage II and stage III RC patients received neoadjuvant long course chemoradiation (LCCRT) then Surgery then adjuvant chemotherapy (AC) (52%). Most common AC used was Capecitabine-Oxaliplatin. At the time of analysis, 57.6% had no evidence of disease while 38.4% progressed or metastasized to distant organs. In the overall population of RC in the young, median overall survival was 21.3 months (mos). Survival rate at 12 mos was 60% and at 24 mos was 40%.
Conclusions
RC in the young Filipino patient presented more with lower lying rectal tumors, moderately to poorly differentiated histology, and more advanced disease at diagnosis. Survival appeared to be worse compared to historical data. Improved understanding of this specific subgroup is necessary for better treatment options and outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
89P - Radiotherapy followed by camrelizumab for unresectable biliary tract cancer: A phase II clinical trial
Presenter: Zhenwei Peng
Session: Poster viewing 02
90P - Feasibility of using tumor-informed circulating tumor DNA (ctDNA)-based testing for patients with anal squamous cell carcinoma
Presenter: Georges Azzi
Session: Poster viewing 02
92P - Safety of liver resection following atezolizumab plus bevacizumab treatment in hepatocellular carcinoma (HCC) patients with macrovascular invasion: A pre-specified analysis of the TALENTop study
Presenter: Huichuan Sun
Session: Poster viewing 02
93P - Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Takuji Okusaka
Session: Poster viewing 02
94P - The treatment burden of neoadjuvant carboplatin/paclitaxel versus 5-fluorouracil/cisplatin in combination with radiotherapy for patients with esophageal cancer
Presenter: Chun-Ling Chi
Session: Poster viewing 02
95P - Additional survival follow-up of TACTICS-L: Transcatheter arterial chemoembolization therapy (TACE) in combination strategy with lenvatinib in (LEN) patients with unresectable hepatocellular carcinoma in Japan
Presenter: Yoshitaka Inaba
Session: Poster viewing 02
96P - Preoperative chemotherapy flot vs dox in patients of locally advanced gastric adenocarcinoma
Presenter: POORNIMA DEVI UTHAYAKUMAR
Session: Poster viewing 02
97P - BEAR study: A single-arm, phase II trial of BI-754091 and afatinib for refractory esophageal squamous cell carcinoma
Presenter: Nai-Jung Chiang
Session: Poster viewing 02